Post-hematopoietic stem cell transplant squamous cell carcinoma in patients with Fanconi anemia: a dreadful enemy
Clin. transl. oncol. (Print)
; 24(2): 388-392, febrero 2022.
Article
en En
| IBECS
| ID: ibc-203444
Biblioteca responsable:
ES1.1
Ubicación: ES15.1 - BNCS
ABSTRACT
IntroductionHematopoietic stem cell transplantation (HSCT) is a curative option for patients with Fanconi anemia (FA) and hematological manifestations but it does not prevent solid tumors, especially squamous cell carcinomas (SCC).MethodsRetrospective study in 22 FA patients who had received HSCT and had been followed up beyond 2 years after HSCT.ResultsThe median follow-up was 15 years. Six patients developed head-and-neck SCC after transplantation. The cumulative incidence of SCC at 15 and 30 years from the HSCT was 14.2% and 71.2%, respectively. One patient was diagnosed in stage IV and the rest, who were being followed up in cancer screening programs, in stage I. Treatment of SCC consisted of surgery in all patients; radiotherapy and chemotherapy were used in two patients and were poorly tolerated.ConclusionFA patients have high risk of head-and-neck SCC. Multi-disciplinary programs for early cancer detection are of special relevance in these patients.
Palabras clave
Texto completo:
1
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Carcinoma de Células Escamosas
/
Trasplante de Células Madre Hematopoyéticas
/
Anemia de Fanconi
/
Neoplasias de Cabeza y Cuello
Límite:
Humans
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Año:
2022
Tipo del documento:
Article